Get the Stockscreener App
11.77
3.29%
-0.40
Benitec Biopharma Inc stock is traded at $11.77, with a volume of 7,640.
It is down -3.29% in the last 24 hours and down -2.73% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$12.17
Open:
$12.18
24h Volume:
7,640
Relative Volume:
0.15
Market Cap:
$282.54M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.0747
EPS:
-10.9518
Net Cash Flow:
$-18.07M
1W Performance:
+8.28%
1M Performance:
-2.73%
6M Performance:
+47.49%
1Y Performance:
+289.74%
1-Day Range:
$11.89
$12.18
1-Week Range:
$10.75
$12.30
52-Week Range:
$2.70
$13.29
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
11.90 | 282.54M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.85 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.46 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
666.65 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.62 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.90 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Institutional investors are Benitec Biopharma Inc.'s (NASDAQ:BNTC) biggest bettors and were rewarded after last week's US$33m market cap gain - Simply Wall St
Benitec Biopharma (NASDAQ:BNTC) Share Price Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Benitec Biopharma (BNTC) to Release Earnings on Monday - MarketBeat
(BNTC) Technical Pivots with Risk Controls - Stock Traders Daily
Franklin Resources Inc. Acquires Significant Stake in Benitec Bi - GuruFocus.com
Benitec Biopharma to Participate in Upcoming Conferences in January and February - GlobeNewswire
BNTCBenitec Biopharma Inc. Latest Stock News & Market Updates - StockTitan
Benitec Biopharma Announces Three Major Conference Presentations for Early 2025 - StockTitan
Guggenheim Initiates Coverage of Benitec Biopharma (BNTC) with Buy Recommendation - MSN
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Benitec Biopharma Inc. (NASDAQ:BNTC) Given Average Rating of “Buy” by Brokerages - Defense World
Benitec Biopharma: Early Positive Data, Small Target Market, Little Competition - Seeking Alpha
Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update - MarketBeat
Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock - MSN
Benitec Biopharma Inc. (NASDAQ:BNTC) Shares Purchased by Geode Capital Management LLC - Defense World
Benitec Biopharma (NASDAQ:BNTC) Stock Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
(BNTC) Proactive Strategies - Stock Traders Daily
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Brokerages Set Benitec Biopharma Inc. (NASDAQ:BNTC) Price Target at $24.43 - MarketBeat
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Average Rating of “Buy” from Analysts - Defense World
How To Trade (BNTC) - Stock Traders Daily
Benitec Biopharma Inc. (NASDAQ:BNTC) Director Buys $301,971.96 in Stock - MarketBeat
Suvretta capital management buys $527,174 in Benitec Biopharma stock - Investing.com
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why - Yahoo Finance
Equities Analysts Issue Forecasts for BNTC Q2 Earnings - Defense World
Q2 Earnings Estimate for BNTC Issued By HC Wainwright - MarketBeat
Where are the Opportunities in (BNTC) - Stock Traders Daily
Hedge funds investors own a significant stake of 38% in Benitec Biopharma Inc. (NASDAQ:BNTC) - Yahoo Finance
Benitec Biopharma stock soars to 52-week high of $13.29 By Investing.com - Investing.com South Africa
Benitec Biopharma stock soars to 52-week high of $13.29 - Investing.com
Benitec Biopharma (NASDAQ:BNTC) Now Covered by HC Wainwright - Defense World
Benitec Biopharma initiated with a Buy at H.C. Wainwright - Yahoo Finance
Benitec Biopharma's SWOT analysis: gene therapy stock shows promise in OPMD - Investing.com
Benitec Biopharma announces executive team changes - Investing.com
Benitec Biopharma (NASDAQ:BNTC) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
Benitec Biopharma announces executive team changes By Investing.com - Investing.com Australia
Benitec Biopharma (NASDAQ:BNTC) Appoints New Chief Operating Officer and Makes Changes to Executive Officers’ Roles and Compensation - Defense World
Short Interest in Benitec Biopharma Inc. (NASDAQ:BNTC) Grows By 6.9% - MarketBeat
Robert W. Baird Begins Coverage on Benitec Biopharma (NASDAQ:BNTC) - Defense World
Benitec Biopharma Shakes Up Management Team - MarketWatch
Baird Initiates Coverage of Benitec Biopharma (BNTC) with Outperform Recommendation - MSN
Benitec Biopharma (NASDAQ:BNTC) Coverage Initiated at Robert W. Baird - MarketBeat
Baird sets $30 target on Benitec BioPharma, cites gene therapy By Investing.com - Investing.com UK
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
Benitec Biopharma approves preferred stock issuance By Investing.com - Investing.com Canada
Benitec Biopharma approves preferred stock issuance - Investing.com
Benitec Biopharma stock soars to 52-week high of $12.95 By Investing.com - Investing.com Canada
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? - Yahoo Finance
When (BNTC) Moves Investors should Listen - Stock Traders Daily
Benitec Biopharma shareholders approve key proposals By Investing.com - Investing.com Canada
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 03 '24 |
Buy |
9.60 |
42,000 |
403,200 |
7,957,365 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 20 '24 |
Buy |
10.22 |
27,436 |
280,396 |
7,920,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
0.43%
3.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):